Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relevant nonmajor bleeding. RESULTS: The primary efficacy outcome occurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in the conventional-therapy group (relative risk, 0.84; 95% confidence interval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage points; 95% CI, -1.3 to 0.4). Apixaban was noninferior to conventional therapy (P<0.001) for predefined upper limits of the 95% confidence intervals for both relative risk (<1.80) and difference in risk (<3.5 percentage points). Major bleeding occurred in 0.6% of patients who received apixaban and in 1.8% of those who received conventional therapy (relative risk, 0.31; 95% CI, 0.17 to 0.55; P<0.001 for superiority). The composite outcome of major bleeding and clinically relevant nonmajor bleeding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the conventional-therapy group (relative risk, 0.44; 95% CI, 0.36 to 0.55; P<0.001). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Self-citationPulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Farrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Cited by
Items 401–500 of 1,003
Nicol, C., Lacut, K., Pan‐Petesch, B., Lippert, É., & Ianotto, J. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1720979 · Cited by 47
A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant
Wadsworth, D. C., Sullivan, E., Jacky, T., Sprague, T., Feinman, H., & Kim, J. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13343 · Cited by 42
Cohen, A. T., Pan, S. M., Byon, W., Ilyas, B. S., Taylor, T., & Lee, T. C. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01716-8 · Cited by 41
“The pre-specified subgroup analysis of the AMPLIFY trial by body weight (B 60,[60 to\100, and C 100 kg) showed no significant differences between apixaban and enoxaparin/warfarin for the outcome of recurrent VTE; furthermore, apixaban-treated patients had a lower rate of major bleeding [11].”
BackgroundMethodResultInfluentialSelf-citationSong, Y. J., Wang, X., Perlstein, I., Wang, J. J., Badawy, S. I. F., Frost, C. E., & LaCreta, F. P. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.05.497 · Cited by 41
Gómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A., & Vargas, E. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50543 · Cited by 43
Potential antidotes for reversal of old and new oral anticoagulants
Suryanarayan, D., & Schulman, S. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50026-6 · Cited by 42
“It was non-inferior to warfarin in treatment of VTE and was associated with significantly lower bleeding rates [29].”
BackgroundHow can we reverse bleeding in patients on direct oral anticoagulants?
Crowther, M. A., & Cuker, A. C. (2018) · Kardiologia Polska · doi:10.5603/kp.a2018.0197 · Cited by 43
Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban
Houghton, D. E., Casanegra, A. I., Peterson, L. G., Cochuyt, J. J., Hodge, D. O., Vlazny, D. T., McBane, R. D., Froehling, D. A., & Wysokiński, W. E. (2020) · American Journal of Hematology · doi:10.1002/ajh.25820 · Cited by 39
Alhousani, M. M., Malik, S. U., Abu-Hashyeh, A., Poznanski, N. J., Al-Hasan, S., Roth, D. F., Alsharedi, M. F., & Mustafa, B. O. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.11.036 · Cited by 40
Ellenbogen, M. I., Ardeshir‐Rouhani‐Fard, S., Segal, J. B., Streiff, M. B., Deitelzweig, S. B., & Brotman, D. J. (2022) · Journal of Hospital Medicine · doi:10.1002/jhm.12926 · Cited by 47
Wang, X., Ma, Y., Xu, H., Li, M., Li, J., Tian, J., Wang, Q., Yan, P., Li, J., Xie, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956.pub3 · Cited by 52
Lippi, G., Ardissino, D., Quintavalla, R., & Cervellin, G. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1082-5 · Cited by 38
“It is also noteworthy that an increasing number of clinical trials are demonstrating that this new class of drugs display a highly favourable profile of efficacy and safety in treatment and prophylaxis of venous thromboembolism (VTE) [11–13].”
BackgroundSaraf, K., Morris, P., Garg, P., Sheridan, P. J., & Storey, R. F. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-132605 · Cited by 42
Sun, M. T., Wood, M. K., Chan, W. O., Selva, D. N., Sanders, P., Casson, R. J., & Wong, C. X. J. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.2199 · Cited by 46
Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges
Frère, C., Benzidia, I., Marjanovic, Z., & Farge, D. (2019) · Cancers · doi:10.3390/cancers11010071 · Cited by 40
Cohen, A. T., Sah, J., Lee, T. T. H., Rosenblatt, L. C., Hlavacek, P., Emir, B., Keshishian, A. V., Yüce, H., & Luo, X. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020200 · Cited by 42
“In the AMPLIFY trial, apixaban was noninferior to enoxaparin followed by warfarin for the treatment of VTE, with a significantly lower risk of MB [12].”
MethodSelf-citationUpdated recommendations for the treatment of venous thromboembolism
Hong, J., Ahn, S., Lee, Y. J., Lee, J. H., Han, J. W., Kim, K. H., Yhim, H., Nam, S., Kim, H., Song, J., et al. (2021) · Blood Research · doi:10.5045/br.2021.2020083 · Cited by 42
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis.
Wang, K.-L., Chu, P. H., Lee, C., Pai, P. Y., Lin, P.-Y., Shyu, K. G., Chang, W., Chiu, K., Huang, C.-L., Lee, C. Y., et al. (2016) · Europe PMC (PubMed Central) · doi:10.6515/acs20151228a · Cited by 49
Cohen, A. T., Imfeld, S., & Rider, T. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0119-7 · Cited by 40
“In AMPLIFY, the apixaban arm had 64% of patients with a creatinine clearance [80 ml/min and approximately 6% of patients had a creatinine clearance \50 ml/min [25].”
BackgroundMethodInfluentialSelf-citationReiffel, J. A., Weitz, J. I., Reilly, P. A., Kaminskas, E., Sarich, T. C., Sager, P. T., & Seltzer, J. H. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.04.010 · Cited by 38
Self-citationAnticoagulantes orales directos: puesta al día
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.11.042 · Cited by 39
Shaw, J. R., Woodfine, J. D., Douketis, J. D., Schulman, S., & Carrier, M. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12076 · Cited by 39
The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
Al-Samkari, H. T., & Connors, J. M. (2018) · Cancers · doi:10.3390/cancers10080271 · Cited by 41
“trials [29-33] demonstrating non-inferiority for preventing recurrent VTE.”
BackgroundRivaroxaban and the EINSTEIN clinical trial programme
Cohen, A. T., & Bauersachs, R. M. (2019) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000800 · Cited by 43
Self-citationFuentes, H. E., McBane, R. D., Wysokiński, W. E., Tafur, A. J., Loprinzi, C. L., Murad, M. H., & Riaz, I. B. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.05.035 · Cited by 41
Use of Direct Oral Anticoagulants in Morbidly Obese Patients
Kido, K., Lee, J. C., Hellwig, T. R., & Gulseth, M. P. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2353 · Cited by 38
Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide
Kow, C. S., Sunter, W., Bain, A., Zaidi, S. T. R., & Hasan, S. S. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00415-z · Cited by 37
Liu, X., Johnson, M. R., Mardekian, J., Phatak, H. M., Thompson, J. R., & Cohen, A. T. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002340 · Cited by 45
“Patients were assigned to receive apixaban, 10 mg twice daily for the first 7 days, followed by 5 mg twice daily for 23 weeks, or enoxaparin 1 mg/kg of body weight every 12 hours for at least 5 days, followed by warfarin, begun concomitantly, for 6 months.(12) Randomization was performed with the use of an interactive…”
BackgroundMethodResultInfluentialSelf-citationDirect oral anticoagulants and venous thromboembolism
Franchini, M., & Mannucci, P. M. (2016) · European Respiratory Review · doi:10.1183/16000617.0025-2016 · Cited by 40
Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Bea, S., Iyer, G. S., Kim, D., Lin, K. J., Zhang, Y., Zakoul, H., Tesfaye, H., & Bykov, K. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.1109 · Cited by 39
Frost, C. E., Cui, Y., Song, Y. J., Wang, J. J. J., Yu, Z., Schuster, A. E., & Barrett, Y. C. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s51981 · Cited by 38
“Apixaban is also being developed for the treatment of venous thromboembolism.(6,7) Variations in the pharmacokinetic and pharmacodynamic properties of anticoagulants such as heparin and warfarin, as well as resulting clotting times, were observed among different racial groups, including different Asian ethnicities.”
BackgroundWho, when, and how to reverse non-vitamin K oral anticoagulants
Aronis, K. N., & Hylek, E. M. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1297-0 · Cited by 39
Polymeris, A. A., Traenka, C., Hert, L., Seiffge, D. J., Peters, N., Marchis, G. M. D., Bonati, L. H., Lyrer, P. A., & Engelter, S. T. (2016) · European Neurology · doi:10.1159/000450750 · Cited by 36
Anticoagulation at the extremes of body weight: choices and dosing
McCaughan, G. J. B., Favaloro, E. J., Pasalic, L., & Curnow, J. L. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1517040 · Cited by 36
“In AMPLIFY, there was no difference with regards to efficacy or safety in patients weighing ≤60 kg [75].”
BackgroundMethodMaughan, B. C., Frueh, L., McDonagh, M. S., Casciere, B., & Kline, J. A. (2020) · Academic Emergency Medicine · doi:10.1111/acem.14108 · Cited by 41
Fernandez‐Martinez, S., Lenoir, C., Samer, C. F., & Rollason, V. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.647 · Cited by 39
Панченко, Е. П., Balahonova, T. V., Danilov, N. M., Komarov, A. L., Станиславовна, К. Е., Saidova, M. A., Shakhmatova, O. O., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-1-44-77 · Cited by 39
Caldeira, D., Canastro, M., Barra, M., Ferreira, A., Costa, J. N., Pinto, F. J., & Ferreira, J. J. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.0985 · Cited by 39
Mandernach, M. W., Beyth, R. J., & Rajasekhar, A. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s68010 · Cited by 40
“In the AMPLIFY-EXT study, Agnelli et al further evaluated the use of apixaban for extended prophylaxis following initial treatment for VTE.”
InfluentialJennings, I., Kitchen, D. P., Keeling, D. M., Fitzmaurice, D. A., & Heneghan, C. J. (2014) · British Journal of Haematology · doi:10.1111/bjh.13070 · Cited by 36
“…viable alternatives to warfarin (Connolly et al, 2009; Schulman et al, 2009, 2013; Bauersachs et al, 2010; Granger et al, 2011; Buller et al, 2012; Agnelli et al, 2013a,b; Giugliano et al, 2013; Hokusai-Investigators, 2013), and these drugs have received National Institute for Health and Care…”
BackgroundYamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.02.029 · Cited by 36
Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants
Wharin, C., & Tagalakis, V. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.11.001 · Cited by 36
Cancer-associated thrombosis: investigating the role of new oral anticoagulants
Franchini, M., Bonfanti, C., & Lippi, G. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.02.024 · Cited by 38
“In the randomized, double-blind AMPLIFY trial [26], apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily for 6 months) was non-inferior to conventional therapy with enoxaparin/warfarin for treatment of acute VTE (recurrent VTE: 2.”
BackgroundMethodInfluentialNon-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome
Sciascia, S., López-Pedrera, C., Cecchi, I., Pecoraro, C., Roccatello, D., & Cuadrado, M. J. (2016) · Rheumatology · doi:10.1093/rheumatology/kev445 · Cited by 36
Direct oral anticoagulants in hypercoagulable states
Kunk, P. R., Brown, J. T., McShane, M., Palkimas, S., & Macik, B. G. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1420-x · Cited by 35
“While medication compliance, especially with twice daily apixaban is a concern, the etiology of these recurrent VTEs is difficult to uncover, but may have occurred regardless of the anticoagulant used.”
BackgroundInfluentialApixaban and rivaroxaban in patients with cerebral venous thrombosis
Covut, F., Kewan, T. Z., Perez, O., Flores, M., Haddad, A. S., & Daw, H. A. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.11.018 · Cited by 35
Venous thromboembolism: A clinician update
Serhal, M., & Barnes, G. D. (2019) · Vascular Medicine · doi:10.1177/1358863x18821159 · Cited by 37
Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE
Bounameaux, H., Haas, S. K., Farjat, A. E., Ageno, W., Weitz, J. I., Goldhaber, S. Z., Turpie, A. G. G., Goto, S., Angchaisuksiri, P., Nielsen, J. D., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.036 · Cited by 35
Self-citationThromboembolism in Older Adults
Gross, P. L., & Chan, N. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.470016 · Cited by 36
“But, given that lower doses of apixaban and rivaroxaban have been validated as being effective and with a trend to less clinically relevant bleeding in extended treatment of unprovoked VTE and VTE provoked by minor risk factors (81, 86), it seems reasonable to consider these lower doses in elderly patients who need or…”
BackgroundBiase, L. D., Lakkireddy, D. J., Marazzato, J., Velasco, A., Díaz, J. C., Navara, R., Chrispin, J., Rajagopalan, B., Natale, A., Mohanty, S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.09.831 · Cited by 38
Touma, L., Filion, K. B., Atallah, R., Eberg, M., & Eisenberg, M. J. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.11.039 · Cited by 34
Lullo, L. D., Ronco, C., Cozzolino, M. G., Russo, D., Russo, L., Iorio, B. R. D., Pascalis, A. D., Bàrbera, V., Galliani, M., Vitaliano, E., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.04.027 · Cited by 34
Wood, B., Nascimento, B., Rizoli, S. B., Sholzberg, M., McFarlan, A., Phillips, A., & Ackery, A. (2017) · Scandinavian Journal of Trauma Resuscitation and Emergency Medicine · doi:10.1186/s13049-017-0420-y · Cited by 34
Rigano, J., Ng, C., Nandurkar, H. H., & Ho, P. W. (2017) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000678 · Cited by 36
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
Caterina, R. D., Ageno, W., Agnelli, G., Chan, N., Diener, H., Hylek, E. M., Raskob, G. E., Siegal, D. M., Verheugt, F. W. A., Lip, G. Y. H., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1675816 · Cited by 37
Self-citationPediatric deep venous thrombosis
Audu, C. O., Wakefield, T. W., & Coleman, D. M. (2019) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2018.12.012 · Cited by 34
Direct oral anticoagulants in chronic kidney disease: an update
Mavrakanas, T. A., Charytan, D. M., & Winkelmayer, W. C. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000634 · Cited by 39
Adedeji, A., Chukwura, O., Obafemi, T., McNulty, S. B., & Reinert, J. P. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020957620 · Cited by 36
A review of upper extremity deep vein thrombosis
Khan, O., Marmaro, A., & Cohen, D. A. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1892390 · Cited by 38
Chazova, I. E., Ageev, F. T., Владимировна, А. А., Vicenya, M. V. V., Gilyarov, M. Y., Martynyuk, T. V., Панченко, Е. П., Poltavskaya, M. G., Potievskaya, V. I., Trofimova, O. P., et al. (2022) · Eurasian heart journal · doi:10.38109/2225-1685-2022-1-6-79 · Cited by 36
Pawar, A. M., Gagne, J. J., Gopalakrishnan, C., Iyer, G. S., Tesfaye, H., Brill, G. E., Chin, K., & Bykov, K. (2022) · JAMA · doi:10.1001/jama.2022.1920 · Cited by 34
Genge, L., Krala, A., Tritschler, T., Gal, G. L., Langlois, N., Dubois, S., West, C., Duffett, L. D., & Skeith, L. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15788 · Cited by 37
Hillis, C., & Crowther, M. A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1036 · Cited by 36
“001) in the composite of major and non-major clinically relevant bleeding compared to warfarin (34).”
BackgroundMismetti, P., Laporte, S., & Pellerin, O. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.11.006 · Cited by 38
Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis
Maura, G., Billionnet, C., Coste, J., Weill, A., Neumann, A., & Pariente, A. (2018) · Drug Safety · doi:10.1007/s40264-018-0668-9 · Cited by 34
Andexanet Alfa for Factor Xa Inhibitor Reversal
Connolly, S. J., Gibson, C. M., & Crowther, M. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1613270 · Cited by 34
Oh, H. J., Ryu, K. H., Park, B. J., & Yoon, B. (2021) · Medicine · doi:10.1097/md.0000000000025216 · Cited by 34
Thrombosis and Aging: Fibrin Clot Properties and Oxidative Stress
Konieczyńska, M., Natorska, J., & Undas, A. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0365 · Cited by 40
“In contrast to warfarin, age > 75 years did not increase the bleeding rates in rivaroxaban-treated patients (Agnelli et al., 2013; Buller et al., 2013; Prins et al., 2013; Schulman et al., 2014).”
Lee, F. M. H., Chan, A. K. C., Lau, K. K., & Chan, H. H. W. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.01.031 · Cited by 37
Amin, A., Bruno, A. S., Trocio, J. N., Lin, J., & Lingohr-Smith, M. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1007210 · Cited by 37
Tornyos, A., Kehl, D., D’Ascenzo, F., & Komócsi, A. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.12.001 · Cited by 36
Efficacy and safety of novel anticoagulants in the elderly.
Karamichalakis, N., Georgopoulos, S., Vlachos, K. G., Liatakis, I., Efremidis, M., Sideris, A., & Letsas, Κ. P. (2016) · PubMed Central · doi:10.11909/j.issn.1671-5411.2016.08.011 · Cited by 39
Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis
Kupó, P., Szakács, Z., Solymár, M., Habon, T., Czopf, L., Haţegan, L., Csányi, B., Borbás, J., Tringer, A., Varga, G., et al. (2019) · Angiology · doi:10.1177/0003319719874255 · Cited by 35
Antithrombotic Drugs—Pharmacology and Perspectives
Li, T., Deshan, Y., & Yuan, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_4 · Cited by 36
Goldenberg, N. A., Takemoto, C. M., Yee, D. L., Kittelson, J. M., & Massicotte, M. P. (2015) · Blood · doi:10.1182/blood-2015-06-651539 · Cited by 33
Wu, C. M., Alotaibi, G., AlSaleh, K. A., & McMurtry, M. S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.07.001 · Cited by 34
“Results: Of the 2453 citations retrieved, 5 RCTs that enrolled 24,507 patients were included.”
MethodInfluentialContemporary management of acute and chronic deep venous thrombosis
Saha, P., Black, S. A., Breen, K. A., Patel, A. S., Modarai, B., & Smith, A. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw006 · Cited by 37
Wille, K., Sadjadian, P., Becker, T. M., Kolatzki, V., Horstmann, A., Fuchs, C., & Grießhammer, M. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3483-6 · Cited by 34
Prognosis of patients with pulmonary embolism after rehabilitation
Amoury, M., NOACK, F., Kleeberg, K., Stoevesandt, D., Lehnigk, B., Bethge, S., Heinze, V., & Schlitt, A. (2018) · Vascular Health and Risk Management · doi:10.2147/vhrm.s158815 · Cited by 33
“7% died.(10) However, in these studies, the rate of recurrent VTE was comparable (~2.”
BackgroundDirect Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations
Elhosseiny, S., Moussawi, H. A., Chalhoub, J. M., Lafferty, J., & Deeb, L. S. (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/4383269 · Cited by 33
Mukdad, M. A., Al‐Badriyeh, D., & Elewa, H. F. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619849103 · Cited by 34
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism
Giustozzi, M., Franco, L., Vedovati, M. C., Becattini, C., & Agnelli, G. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01878-x · Cited by 38
Self-citationBrekelmans, M. P. A., Ageno, W., Beenen, L. F. M., Brenner, B., Buller, H. R., Chen, C. Z., Cohen, A. T., GROSSO, M. A., Meyer, G., Raskob, G. E., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30080-1 · Cited by 32
Self-citationRiess, H. B., Ay, C., Bauersachs, R. M., Becattini, C., Beyer‐Westendorf, J., Cajfinger, F., Chau, I., Cohen, A. T., Khorana, A. A., Maraveyas, A., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0473 · Cited by 33
Self-citationZakai, N. A., Walker, R. F., MacLehose, R. F., Adam, T. J., Alonso, Á., & Lutsey, P. L. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14303 · Cited by 33
Current status of oral anticoagulant reversal strategies: a review
Rawal, A., Ardeshna, D. R., Minhas, S., Cave, B. E., Ibeguogu, U., & Khouzam, R. N. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.101 · Cited by 33
“3% during the 6-month therapy length (13,14).”
Bonnefoy, P. B., Margelidon-Cozzolino, V., Catella, J., Ayoub, E., Guichard, J.-B., Murgier, M., & Bertoletti, L. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.09.038 · Cited by 32
Najidh, S., Versteeg, H. H., & Buijs, J. T. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2019.12.022 · Cited by 32
Prevention of venous thromboembolism in ambulatory patients with cancer
Khorana, A. A., Cohen, A. T., Carrier, M., Meyer, G., Pabinger, I., Kavan, P., & Wells, P. S. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000948 · Cited by 32
Self-citationOnundarson, P. T., Francis, C. W., Indridason, Ó. S., Arnar, D. O., Bjornsson, E. S., Magnússon, M. K., Júlíusson, S., Jensdottir, H. M., Viðarsson, B., Gunnarsson, P., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00073-3 · Cited by 32
Bouée, S., Emery, C., Samson, A., Gourmelen, J., Bailly, C., & Cotté, F.-E. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0078-0 · Cited by 38
“8 % of patients [13, 14, 29, 30].”
ResultPathogenesis, Diagnosis, and Treatment of Venous Thromboembolism in Older Adults
Johnson, S. A., Eleazer, G. P., & Rondina, M. T. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14279 · Cited by 35
Preclinical and clinical data for factor Xa and “universal” reversal agents
Milling, T. J., & Kaatz, S. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.09.052 · Cited by 32
Dobrowolski, C., Clark, E. G., & Sood, M. M. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1437-1 · Cited by 33
Weitz, J. I., Jaffer, I., & Fredenburgh, J. C. (2017) · F1000Research · doi:10.12688/f1000research.11174.1 · Cited by 38
Self-citationClinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism
Moustafa, F., Giorgi‐Pierfranceschi, M., Micco, P. D., Bucherini, E., Lorenzo, A., Villalobos, A., Nieto, J. A., Valero, B., Samperiz, A. L., Monréal, M., et al. (2017) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12036 · Cited by 34
Direct oral anticoagulants: An update
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.07.005 · Cited by 34
Barbui, T., Stefano, V. D., Falanga, A., Finazzi, G., Martinelli, I., Rodeghiero, F., Vannucchi, A. M., & Barosi, G. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0225-5 · Cited by 32
Baumgartner, C., Klok, F. A., Carrier, M., Limacher, A., Moor, J., Righini, M., Beer, J. H., Peluso, M., Rakovic, D., Huisman, M. V., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040151 · Cited by 33
Shaw, J. R., de Wit, C., Gal, G. L., & Carrier, M. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13670 · Cited by 31
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- Pfizer (United States) (US)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-29
- Volume
- 369
- Issue
- 9
- Pages
- 799-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166402206
- Cited by
- 2,324
- References
- 13
- Citations by year
- 2026: 109 · 2025: 101 · 2024: 134 · 2023: 134 · 2022: 162 · 2021: 193 · 2020: 224 · 2019: 193 · 2018: 213 · 2017: 191 · 2016: 234 · 2015: 198 · 2014: 184 · 2013: 51
- FWCI
- 194.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, acute venous thromboembolism, factor Xa inhibitors, oral anticoagulation, enoxaparin, warfarin, recurrent venous thromboembolism, major bleeding, non-inferiority, fixed-dose regimen, direct oral anticoagulants, anticoagulation duration, venous thromboembolism
- MeSH terms
- Acute Disease, Administration, Oral, Adult, Aged, Anticoagulants, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Warfarin, Treatment Outcome, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.